2026 Q3 Portfolio Activity
In 2026 Q3, Propel Bio Management, LLC maintained a portfolio of 34 distinct positions. The most significant new addition was COLLEGIUM PHARMACEUTICAL, now representing 4.75% of the total fund value. They heavily accumulated shares in MAZE THERAPEUTICS INC, increasing the position by 338.4%. Conversely, Propel Bio Management, LLC completely exited their position in ZEVRA THERAPEUTICS INC.
Position History
hover any row below to update
Loading…
Total Positions
34
Quarter
2026 Q3
Top Holding
PAGP (17.5%)
Top 10 Concentration
68.3%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-34 of 34
Propel Bio Management, LLC Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PAGP
PLAINS GP HOLDI...
|
Energy | 17.47% | 16.16% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
1,272,360 | $32,954,124 |
$12.83
+104.3%
|
2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
ACHV
ACHIEVE LIFE SC...
|
Healthcare | 16.57% | 13.79% |
#2
Prev: #2
|
6.0 |
—
|
-169,870 | -4.2% |
P
S
|
3,864,148 | $31,260,957 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
DCTH
DELCATH SYSTEMS...
|
Healthcare | 5.12% | 5.74% |
#3
2
Prev: #5
|
3.0 |
—
|
-266,796 | -30.6% |
P
S
|
604,664 | $9,656,484 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
COLL
COLLEGIUM PHARM...
|
Healthcare | 4.75% | — |
#4
Prev: #—
|
5.9 |
—
|
410,175 | — |
NEW
|
410,175 | $8,950,019 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
CORT
CORCEPT THERAPE...
|
Healthcare | 4.60% | 6.21% |
#5
2
Prev: #3
|
2.3 |
—
|
-61,225 | -44.9% |
P
S
|
75,274 | $8,673,823 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
AQST
AQUESTIVE THERA...
|
Healthcare | 4.56% | 3.14% |
#6
5
Prev: #11
|
1.8 |
—
|
-1,163,674 | -80.7% |
P
S
|
278,723 | $8,608,753 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
MIST
MILESTONE PHARM...
|
Healthcare | 4.34% | 5.21% |
#7
1
Prev: #6
|
4.2 |
—
|
2,020,137 | 27.2% |
P
S
|
9,449,727 | $8,180,629 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
PHAT
PHATHOM PHARMAC...
|
Healthcare | 4.28% | 5.96% |
#8
4
Prev: #4
|
3.7 |
—
|
55,555 | 5.3% |
P
S
|
1,105,913 | $8,073,165 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 3.62% | 4.24% |
#9
2
Prev: #7
|
1.9 |
—
|
-23,900 | -4.2% |
P
S
|
549,186 | $6,831,874 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
OBIO
ORCHESTRA BIOME...
|
Healthcare | 2.96% | 2.02% |
#10
6
Prev: #16
|
2.2 |
—
|
no change | no change |
P
S
|
896,701 | $5,577,480 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 2.77% | 0.68% |
#11
16
Prev: #27
|
4.1 |
—
|
148,200 | 338.4% |
P
S
|
191,998 | $5,218,506 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ABEO
ABEONA THERAPEU...
|
Healthcare | 2.66% | 3.18% |
#12
2
Prev: #10
|
1.6 |
—
|
-27,063 | -2.8% |
P
S
|
956,007 | $5,019,037 | 2024 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ARTV
ARTIVA BIOTHERA...
|
Healthcare | 2.63% | 3.54% |
#13
4
Prev: #9
|
2.1 |
—
|
no change | no change |
P
S
|
696,436 | $4,958,624 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
KYTX
KYVERNA THERAPE...
|
Healthcare | 2.53% | 4.12% |
#14
6
Prev: #8
|
1.0 |
—
|
-182,603 | -20.7% |
P
S
|
700,595 | $4,764,046 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
IVA
INVENTIVA SA - ...
|
Healthcare | 2.22% | 2.53% |
#15
1
Prev: #14
|
1.4 |
—
|
-147,258 | -11.5% |
P
S
|
1,133,954 | $4,184,290 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
CABA
CABALETTA BIO I...
|
Healthcare | 2.09% | — |
#16
Prev: #—
|
4.3 |
—
|
2,049,471 | — |
NEW
|
2,049,471 | $3,934,984 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 2.00% | 2.20% |
#17
2
Prev: #15
|
2.8 |
—
|
110,844 | 10.3% |
P
S
|
1,187,422 | $3,764,128 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
PROK
PROKIDNEY CORP
|
Healthcare | 1.77% | — |
#18
Prev: #—
|
4.2 |
—
|
2,009,733 | — |
NEW
|
2,009,733 | $3,336,157 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
CRVS
CORVUS PHARMACE...
|
Healthcare | 1.61% | 0.55% |
#19
9
Prev: #28
|
3.6 |
—
|
193,930 | 275.5% |
P
S
|
264,310 | $3,044,851 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
PALI
PALISADE BIO IN...
|
Healthcare | 1.59% | 2.82% |
#20
8
Prev: #12
|
1.1 |
—
|
-358,199 | -13.9% |
P
S
|
2,224,189 | $3,002,655 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 1.46% | 1.84% |
#21
2
Prev: #19
|
1.6 |
—
|
no change | no change |
P
S
|
357,966 | $2,745,599 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SCYX
SCYNEXIS INC
|
Healthcare | 1.42% | 1.16% |
#22
2
Prev: #24
|
1.1 |
—
|
-2,004 | -0.4% |
P
S
|
541,474 | $2,674,882 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
FDMT
4D MOLECULAR TH...
|
Healthcare | 1.36% | 1.76% |
#23
3
Prev: #20
|
0.5 |
—
|
-73,500 | -29.1% |
P
S
|
179,154 | $2,563,694 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
OVID
OVID THERAPEUTI...
|
Healthcare | 1.34% | 1.57% |
#24
3
Prev: #21
|
1.0 |
—
|
-96,817 | -8.7% |
P
S
|
1,018,721 | $2,536,615 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
IMUX
IMMUNIC INC
|
Healthcare | 1.17% | 2.61% |
#25
12
Prev: #13
|
0.5 |
—
|
-88,288 | -27.2% |
P
S
|
236,734 | $2,201,626 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
UPB
UPSTREAM BIO IN...
|
Healthcare | 0.94% | 1.27% |
#26
3
Prev: #23
|
0.9 |
—
|
-15,000 | -4.3% |
P
S
|
335,389 | $1,767,500 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
IRD
OPUS GENETICS I...
|
Healthcare | 0.69% | — |
#27
Prev: #—
|
3.8 |
—
|
270,036 | — |
NEW
|
270,036 | $1,306,974 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 0.65% | 2.02% |
#28
11
Prev: #17
|
0.3 |
—
|
-66,156 | -63.8% |
P
S
|
37,539 | $1,216,639 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
N/A
SPYGLASS PHARMA...
|
|
Unknown | 0.57% | — |
#29
Prev: #—
|
3.7 |
—
|
41,418 | — |
NEW
|
41,418 | $1,076,868 | — | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
LONA
LEONABIO INC
|
Healthcare | 0.28% | 0.72% |
#30
4
Prev: #26
|
1.1 |
—
|
no change | no change |
P
S
|
149,279 | $532,926 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SGMT
SAGIMET BIOSCIE...
|
Healthcare | 0.00% | 0.51% |
Sold All 😨
(Was: #29) |
0.0 |
—
|
-125,878 | -100.0% |
CLOSED
|
— | $— | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SLN
SILENCE THERAPE...
|
Healthcare | 0.00% | 1.10% |
Sold All 😨
(Was: #25) |
0.0 |
—
|
-191,733 | -100.0% |
CLOSED
|
— | $— | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
EYPT
EYEPOINT INC
|
Healthcare | 0.00% | 1.43% |
Sold All 😨
(Was: #22) |
0.0 |
—
|
-191,745 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ZVRA
ZEVRA THERAPEUT...
|
Healthcare | 0.00% | 1.90% |
Sold All 😨
(Was: #18) |
0.0 |
—
|
-253,544 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 |
Showing 1-34 of 34 holdings